Reassessing GLP-1 Drug Safety During Early Pregnancy

A new analysis from Harvard suggests that early pregnancy exposure to GLP-1 drugs, used for diabetes and obesity, is not significantly risky. While not recommended during pregnancy due to unknown fetal safety, unintentional early use does not greatly increase adverse outcomes, although women should follow medical advice.

A comprehensive study suggests early pregnancy exposure to GLP-1 drugs is not significantly dangerous, despite unknown fetal safety.

Conducted at Harvard, the analysis reviewed 3,572 pregnancies involving GLP-1 drug use, finding minimal difference in non-live birth risk with medication continuation vs. its cessation.

Women should heed medical advice on GLP-1 use when pregnant, though unintentional exposure is less alarming now.